drugset / Trial / NCT02179658

A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD)

NCT02179658

Phase 3 Completed 210 enrolled Astellas Pharma Inc
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The primary objective of this study is to investigate the safety and efficacy of OPT-80 versus vancomycin in subjects with Clostridium difficile-associated diarrhea (CDAD).

Timeline

Start
2014-06-23
Primary completion
2016-09-08
Completion
2016-09-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Fidaxomicin Other / unclassified 200 mg Oral
Comparator Vancomycin Other / unclassified 125 mg Oral